NRXS
NYSE MKT HealthcareNeuraxis, Inc. Common Stock
Biotechnology
NeurAxis, Inc., a medical technology company, focuses on developing neuromodulation therapies to address chronic and debilitating conditions in children and adults in the United States. It offers IB-Stim, a percutaneous electrical nerve field stimulation system intended to be used in patients 8 years of age with functional abdominal pain associated with irritable bowel syndrome (IBS), functional dyspepsia (FD) and associated FD nausea symptoms. The company also offers rectal expulsion device, a screening tool that helps to detects evacuation disorders. It sells its products to healthcare companies, such as hospitals and clinics. The company was formerly known as Innovative Health Solutions, Inc. and changed its name to NeurAxis, Inc. in March 2022. NeurAxis, Inc. was founded in 2011 and is headquartered in Carmel, Indiana.
๐ Market Data
| Price | $8.08 |
|---|---|
| Volume | 293,069 |
| Market Cap | 92.96M |
| Beta | 1.890 |
| RSI (14-Day) | 64.9 |
| 200-Day MA | $4.11 |
| 50-Day MA | $6.83 |
| 52-Week High | $8.40 |
| 52-Week Low | $1.94 |
| Forward P/E | -269.33 |
| Price / Book | 25.33 |
๐ฏ Investment Strategy Scores
NRXS scores across each investment strategy. Higher is better for that strategy's goals.
๐ Strategy Interpretation
Best fit: ๐ Moon Shot (86/100) โ this strategy High growth potential (high beta + oversold).
Lowest fit among scored strategies: ๐ Institutional Whale (1/100). No single score is a buy or sell signal โ use multiple lenses together. Learn how to read these scores โ
๐ Learn More
Indicators on this page
Educational articles
Find NRXS in your text
Paste any article, transcript, or post โ the tool will extract NRXS and every other hidden ticker.
Disclaimer: This data is for educational and entertainment purposes only and does not constitute financial advice. Market data may be delayed. Always do your own research before making investment decisions.
Data last updated: 2026-05-01.